SCHEMBL1138006

SCHEMBL1138006

OC/C=C\CN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.65
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
HIF1A Q16665 4/20 0.65
OPRM1 P35372 4/20 0.65
ADRA1A P35348 4/20 0.65
CYP2D6 P10635 3/20 0.65
CYP3A4 P08684 3/20 0.65
CHRM2 P08172 3/20 0.65
ADORA3 P0DMS8 3/20 0.65
CHRM1 P11229 3/20 0.65
DRD2 P14416 3/20 0.65
ADRA2B P18089 3/20 0.65
ADRA2C P18825 3/20 0.65
SLC6A2 P23975 3/20 0.65
HTR2A P28223 3/20 0.65
HRH1 P35367 3/20 0.65
DRD3 P35462 3/20 0.65
HTR2B P41595 3/20 0.65
SLC6A3 Q01959 3/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137978 1.00 LMNA (0.65) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1137980 1.00 LMNA (0.65) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1138126 0.95 LMNA (0.70) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1138128 0.95 LMNA (0.70) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL6554386 0.85 LMNA (0.65) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1137906 0.85 SLC6A9 (0.57) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1137901 0.85 SLC6A9 (0.57) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1137893 0.85 OPRD1 (0.68) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1137896 0.85 OPRD1 (0.68) LMNAMEN1KMT2AHIF1AOPRM1
SCHEMBL1138520 0.81 KCNH2 (0.59) LMNAMEN1KMT2AHIF1AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487810-A2 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES Sun Pharmaceuticals Industries Ltd. (IN) 2004-12-22 EP claimed
WO-2003079970-A2 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2003-10-02 WO claimed
EP-1487810-B9 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES SUN PHARMA ADVANCED RES CO LTD (IN) 2011-02-23 EP disclosed
EP-1487810-B1 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES SUN PHARMA ADVANCED RES CO LTD (IN) 2010-02-17 EP disclosed
US-7297697-B2 with alkenyl moiety substituted at the 1-position of the piperazine unit; useful in the treatment of histamine mediated diseases SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2007-11-20 US disclosed
US-20050107393-A1 4-(diarylmethyl)-1-piperazinyl derivatives SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2005-05-19 US disclosed
EP-1487810-A2 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES Sun Pharmaceuticals Industries Ltd. (IN) 2004-12-22 EP disclosed
WO-2003079970-A2 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107393-A1 4-(diarylmethyl)-1-piperazinyl derivatives NPY2R, NPY1R, CBR3 LMNA 1681/4885MEN1 2759/4885KMT2A 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.